한글목차

세계 iPS 세포 유래 혈소판 시장은 암 및 혈액질환 시장에서의 기회를 배경으로 미래가 기대되는 시장입니다. 이 시장은 2025년부터 2031년까지 9.6%의 연평균 성장률을 보일 것으로 예상됩니다. 주요 성장 요인으로는 첨단 혈소판 치료제에 대한 수요 증가, 재생의료 기술 보급 확대, 세포 기반 혈소판 생산에 대한 연구 진전 등을 꼽을 수 있습니다.

• Lucintel의 예측에 따르면, 유형별로는 예측 기간 동안 생체 내 재생이 더 높은 성장률을 보일 것으로 예상됩니다.
• 용도별로는 혈액질환 분야가 더 높은 성장률을 보일 것으로 예상됩니다.
• 지역별로는 아시아태평양(APAC)이 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.

iPS 세포 유래 혈소판 시장의 새로운 동향

iPS 세포 유래 혈소판 시장은 현재의 제약에 대응하고 임상적 유용성을 확대하기 위한 여러 가지 주요 동향에 따라 계속 진화하고 있습니다. 이러한 추세는 생산 효율성 향상, 안전성 및 품질 확보, 새로운 응용 분야 개척에 초점을 맞추고 있으며, 이러한 추세는 시장의 성장과 보급을 촉진할 것으로 예상됩니다.

• 자동화 및 확장 가능한 생산 : 이 트렌드에서는 바이오리액터와 로봇 시스템을 활용하여 iPS 세포를 혈소판으로 분화시키는 복잡한 과정을 자동화합니다. 이를 통해 생산 수율이 크게 향상되고, 인건비가 절감되며, 제품의 일관성이 향상됩니다. 이는 임상 응용 분야에서 대규모 수요를 충족시키는 데 매우 중요합니다.
• 동종 기성품 : 기업들은 면역 거부반응의 위험을 줄이기 위해 '범용' 유전자 설계를 적용한 iPS 세포주를 개발하고 있습니다. 이러한 추세는 환자별 맞춤화가 필요 없는 범용 기증자 제품의 즉각적인 공급을 가능하게 하고, 수혈의 신속성과 보급 촉진을 통해 시장에 영향을 미치고 있습니다.
• 기능 강화를 위한 유전자 편집 : CRISPR 등의 유전자 편집 툴을 이용하여 iPS 세포를 변형시켜 혈소판 기능 향상, 면역원성 감소, 생산 효율을 향상시키려는 움직임이 확대되고 있습니다. 이를 통해 치료적 특성이 우수하고 효과적이고 안전한 제품을 만들어냈으며, 표준 수혈을 넘어서는 다양한 용도를 통해 시장에 영향을 미치고 있습니다.
• 인공지능의 통합 : 배양 조건의 최적화 및 분화 결과 예측에 AI가 활용되어 개발 프로세스의 효율화가 진행되고 있습니다. AI의 영향은 연구 개발의 가속화, 실험실에서 임상 현장까지의 시간 단축, 제조 공정의 정확성 및 신뢰성 향상에 있습니다.
• 냉동 보존 및 보관에 집중 : 기업들은 iPS 세포 유래 혈소판을 효율적으로 냉동 보존하는 방법을 개발하여 현재 수일 정도인 보존 기간을 연장하고 있습니다. 이러한 추세는 물류에 큰 영향을 미쳐 장거리 운송을 가능하게 하고, 보다 안정적인 공급망을 구축하는 데 큰 영향을 미치고 있습니다. 이는 세계 시장 진출에 필수적인 요소입니다.

이러한 새로운 흐름은 iPS세포 유래 혈소판 시장을 근본적으로 재편하고 있습니다. 자동화, 기성품의 대중화, 유전자 편집을 통한 기능 강화로의 전환은 틈새 기술을 실현 가능하고 확장 가능하며 전 세계적으로 접근 가능한 치료 옵션으로 변화시키고 있습니다.

iPS세포 유래 혈소판 시장의 최근 동향

iPS 세포 유래 혈소판 시장에서는 혁신과 전략적 활동이 급증하고 있습니다. 이러한 발전은 주로 보존 기간의 한계와 기증자 의존성 등 기존 혈소판 공급의 문제를 극복하는 데 초점을 맞추고 있으며, 첨단 생명공학 기술을 활용하여 수혈 의료에서 보다 신뢰할 수 있고 안전한 대안을 창출하고 있습니다.

• 성공적인 임상시험 : 일본에서의 초기 인간 임상시험 완료는 중요한 이정표가 되었습니다. 이번 성과는 규제 당국의 승인에 필수적인 안전성 및 유효성 데이터를 확보하여 iPS 세포 유래 혈소판의 치료 가능성을 입증하고, 향후 대규모 임상 연구로 나아갈 수 있는 발판을 마련했습니다.
• 대량 생산의 진전 : 최적화된 바이오리액터 시스템과 분화 배지를 활용한 새로운 제조 프로토콜을 통해 생산 수율을 크게 향상시켰습니다. 이러한 발전은 기술의 경제적 타당성과 확장성을 높이고 상용화 및 보급의 주요 과제를 해결함으로써 시장에 영향을 미치고 있습니다.
• 보편적 기증자 혈소판에 초점 : 유전자 조작을 통해 '보편적 기증자'로 기능하는 iPS 세포주 개발이 주요 발전입니다. 이는 HLA 적합성에 대한 필요성을 줄여 시장에 영향을 미치고 있으며, 혈소판 수혈의 물류를 간소화하여 보다 광범위한 환자층에게 신속하게 제공할 수 있게 합니다.
• 전략적 제휴 및 공동 연구 : 생명공학 기업, 학술기관, 제약회사 간의 공동 연구가 증가하고 있습니다. 이러한 제휴는 자원, 전문 지식, 자금을 통합하여 연구를 가속화하고, 제품 개발을 효율화하며, 복잡한 규제 상황을 이해하고, 제품 상용화를 앞당겨 시장에 영향을 미치고 있습니다.
• 규제 경로 마련 : 주요 시장의 규제 당국은 iPS 세포 유래 제품을 포함한 세포 치료 기술에 대한 구체적인 가이드라인을 마련하고 있습니다. 이러한 움직임은 시장 승인까지의 경로를 보다 명확하고 예측 가능하게 만들어 투자를 촉진하고 제품이 환자에게 도달하는 시간을 단축시킴으로써 시장에 영향을 미치고 있습니다.

성공적인 임상시험에서 전략적 제휴에 이르기까지 이러한 주요 발전은 종합적으로 iPS 세포 유래 혈소판 시장을 상업적으로 실현 가능한 시장으로 이끌고 있습니다. 이들은 기술적, 경제적, 규제적 장벽을 체계적으로 극복하고 이 분야를 연구 단계에서 전 세계적인 혈소판 부족 및 수혈 관련 문제에 대한 구체적인 해결책으로 전환하고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계 성장 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 iPS 세포 유래 혈소판 시장 : 종류별

• 매력 분석 : 종류별
• 생체내 재생(in vivo)
• 생체외 재생(in vitro)

제5장 세계의 iPS 세포 유래 혈소판 시장 : 용도별

• 매력 분석 : 용도별
• 암
• 혈액질환
• 기타

제6장 지역 분석

제7장 북미의 iPS 세포 유래 혈소판 시장

• 북미의 iPS 세포 유래 혈소판 시장 : 종류별
• 북미의 iPS 세포 유래 혈소판 시장 : 용도별
• 미국의 iPS 세포 유래 혈소판 시장
• 멕시코의 iPS 세포 유래 혈소판 시장
• 캐나다의 iPS 세포 유래 혈소판 시장

제8장 유럽의 iPS 세포 유래 혈소판 시장

• 유럽의 iPS 세포 유래 혈소판 시장 : 종류별
• 유럽의 iPS 세포 유래 혈소판 시장 : 용도별
• 독일의 iPS 세포 유래 혈소판 시장
• 프랑스의 iPS 세포 유래 혈소판 시장
• 스페인의 iPS 세포 유래 혈소판 시장
• 이탈리아의 iPS 세포 유래 혈소판 시장
• 영국의 iPS 세포 유래 혈소판 시장

제9장 아시아태평양의 iPS 세포 유래 혈소판 시장

• 아시아태평양의 iPS 세포 유래 혈소판 시장 : 종류별
• 아시아태평양의 iPS 세포 유래 혈소판 시장 : 용도별
• 일본의 iPS 세포 유래 혈소판 시장
• 인도의 iPS 세포 유래 혈소판 시장
• 중국의 iPS 세포 유래 혈소판 시장
• 한국의 iPS 세포 유래 혈소판 시장
• 인도네시아의 iPS 세포 유래 혈소판 시장

제10장 기타 지역(ROW)의 iPS 세포 유래 혈소판 시장

• ROW의 iPS 세포 유래 혈소판 시장 : 종류별
• ROW의 iPS 세포 유래 혈소판 시장 : 용도별
• 중동의 iPS 세포 유래 혈소판 시장
• 남미의 iPS 세포 유래 혈소판 시장
• 아프리카의 iPS 세포 유래 혈소판 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
• 세계의 iPS 세포 유래 혈소판 시장 최신 동향
• 전략 분석

제13장 밸류체인 전반에 걸친 주요 기업 개요

• 경쟁 분석
• Megakaryon Corporation
• Renerval Therapeutics
• Xueji Shengwu
• Help Therapeutics
• Cynata Therapeutics
• Fate Therapeutics
• Century Therapeutics

제14장 부록

영문목차

The future of the global IPS cell-derived platelets market looks promising with opportunities in the cancer and blood disease markets. The global IPS cell-derived platelets market is expected to grow with a CAGR of 9.6% from 2025 to 2031. The major drivers for this market are the increasing demand for advanced platelet therapies, the rising adoption of regenerative medicine techniques, and the growing research in cell-based platelet production.

• Lucintel forecasts that, within the type category, in vivo regeneration is expected to witness higher growth over the forecast period.
• Within the application category, blood disease is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the IPS Cell-derived Platelets Market

The IPS cell-derived platelets market is evolving with several key trends aimed at addressing current limitations and expanding clinical utility. These trends are centered on improving production efficiency, ensuring safety and quality, and exploring new applications, which will collectively drive the market's growth and accessibility.

• Automation and Scalable Production: This trend involves the use of bioreactors and robotic systems to automate the complex process of differentiating iPSCs into platelets. The impact is a significant increase in production yield, reduced labor costs, and enhanced product consistency, which are crucial for meeting the large-scale demands of clinical applications.
• Allogeneic Off-the-Shelf Products: Companies are developing iPSC lines that are genetically engineered to be "universal," reducing the risk of immune rejection. This trend is impacting the market by enabling the creation of readily available, universal-donor products that do not require patient-specific customization, thus making transfusions faster and more accessible.
• Gene-Editing for Enhanced Functionality: The use of gene-editing tools like CRISPR to modify iPSCs to improve platelet function, reduce immunogenicity, or increase production efficiency is a growing trend. This is impacting the market by creating more effective and safer products with superior therapeutic properties, broadening their use beyond standard transfusions.
• Integration of Artificial Intelligence: AI is being used to optimize culture conditions and predict differentiation outcomes, streamlining the development process. AI's impact is in accelerating research and development, reducing the time from lab to clinic, and improving the accuracy and reliability of manufacturing processes.
• Focus on Cryopreservation and Storage: Companies are developing methods to efficiently cryopreserve IPS cell-derived platelets, extending their shelf life beyond the current few days. This trend is significantly impacting logistics, enabling long-distance transport and creating a more reliable supply chain, which is essential for global market penetration.

These emerging trends are fundamentally reshaping the IPS cell-derived platelets market. The shift towards automation, off-the-shelf products, and enhanced functionality through gene-editing is transforming a niche technology into a viable, scalable, and globally accessible therapeutic option.

Recent Developments in the IPS Cell-derived Platelets Market

The IPS cell-derived platelets market is witnessing a surge in innovation and strategic activity. These developments are primarily focused on overcoming the challenges of traditional platelet supply, such as limited shelf life and donor dependency, by leveraging advanced biotechnologies to create a more reliable and safer alternative for transfusion medicine.

• Successful Clinical Trials: The completion of initial human clinical trials in Japan has marked a significant milestone. This development has provided crucial safety and efficacy data, which is essential for regulatory approval and has demonstrated the therapeutic potential of IPS cell-derived platelets, paving the way for further large-scale clinical investigations.
• Advances in Mass Production: New manufacturing protocols utilizing optimized bioreactor systems and differentiation media have led to a substantial increase in production yield. This development is impacting the market by making the technology more economically viable and scalable, addressing a key challenge to commercialization and widespread adoption.
• Focus on Universal Donor Platelets: The development of iPSC lines that are genetically modified to be "universal donors" is a key development. This is impacting the market by reducing the need for HLA matching, which can simplify the logistics of platelet transfusions and make them more readily available for a broader patient population.
• Strategic Partnerships and Collaborations: There has been an increase in collaborations between biotech companies, academic institutions, and pharmaceutical giants. These partnerships are impacting the market by pooling resources, expertise, and funding to accelerate research, streamline product development, and navigate the complex regulatory landscape, bringing the products closer to commercial reality.
• Regulatory Pathway Development: Regulatory bodies in key markets are establishing specific guidelines for cell-based therapies, including iPSC-derived products. This development is impacting the market by providing a clearer and more predictable path to market approval, encouraging investment and reducing the time required for products to reach patients.

These key developments, from successful clinical trials to strategic collaborations, are collectively driving the IPS cell-derived platelets market toward commercial viability. They are systematically addressing the technical, economic, and regulatory hurdles, transforming the field from a research endeavor into a tangible solution for global platelet shortages and transfusion-related challenges.

Strategic Growth Opportunities in the IPS Cell-derived Platelets Market

The IPS cell-derived platelets market presents significant strategic growth opportunities across various applications. These opportunities are driven by the unique advantages of IPS cell technology, such as scalability and reduced risk of contamination, which enable its application in areas where traditional donor-based platelets are limited.

• Transfusion Medicine: An immediate opportunity lies in addressing the chronic shortage of donor platelets. The ability to produce a consistent and contamination-free supply of platelets from iPSCs is a game-changer. This offers a reliable alternative for patients requiring frequent transfusions, such as those undergoing chemotherapy or with bone marrow disorders.
• Regenerative Medicine: Another key opportunity is the use of IPS cell-derived platelets in regenerative medicine applications. Platelets contain growth factors that can aid in tissue repair and wound healing. Their use in therapies for conditions like chronic wounds, orthopedic injuries, and cardiovascular diseases offers a new avenue for growth and market expansion.
• Drug Discovery and Development: iPSC-derived platelets provide a valuable tool for drug screening and disease modeling. They offer a physiologically relevant human cell model for studying platelet-related disorders and testing new antiplatelet drugs. This application can accelerate the development of new therapeutics and reduce the reliance on animal testing.
• Personalized Medicine: The ability to generate patient-specific platelets from their own iPSCs is a unique opportunity for personalized medicine. This can be particularly impactful for patients with alloimmune refractoriness, who do not respond to donor platelets. This niche application addresses an unmet medical need and can command premium pricing.
• Gene and Cell Therapy: The market can grow by combining iPSC-derived platelets with gene and cell therapies. For example, platelets could be engineered to deliver specific therapeutic genes or molecules. This offers an innovative platform for treating genetic bleeding disorders or as a delivery vehicle for targeted drug delivery.

These strategic growth opportunities are poised to transform the IPS cell-derived platelets market. By expanding beyond traditional transfusion, the market can tap into the burgeoning fields of regenerative medicine, personalized therapy, and drug development, ensuring long-term growth and establishing IPS cell-derived platelets as a cornerstone of future medicine.

IPS Cell-derived Platelets Market Driver and Challenges

The IPS cell-derived platelets market is influenced by a complex interplay of drivers and challenges, which include various technological, economic, and regulatory factors. Understanding these dynamics is crucial for navigating the market, as they dictate the pace of innovation, investment, and ultimately, the commercial viability and patient accessibility of these products.

The factors responsible for driving the IPS cell-derived platelets market include:

1. Shortage of Donor Platelets: The limited shelf life and short supply of donor platelets, which are susceptible to bacterial contamination, is a major driver. This scarcity creates a critical need for an alternative source, which IPS cell technology can address by providing a scalable and on-demand supply.

2. Technological Advancements in Biomanufacturing: Innovations in bioreactor technology and cell culture media have improved the efficiency and yield of iPSC-derived platelet production. These advancements are making the process more cost-effective and reproducible, which is essential for moving from research to large-scale commercial manufacturing.

3. Rising Prevalence of Chronic Diseases: The increasing incidence of chronic diseases like cancer and autoimmune disorders, which often require frequent platelet transfusions, is driving market growth. This demographic trend creates a growing patient population that can benefit from the reliable supply offered by IPS cell-derived platelets.

4. Reduced Risk of Transfusion-Transmitted Infections: IPS cell-derived platelets are produced in a controlled laboratory environment, significantly reducing the risk of viral and bacterial contamination. This inherent safety advantage over donor-derived platelets is a key driver for both patient and physician adoption.

5. Government Funding and Research Initiatives: Favorable government policies and public and private funding for stem cell research are accelerating the development of IPS cell therapies. This financial support helps to fund expensive research and clinical trials, which are necessary to bring products to market.

Challenges in the IPS cell-derived platelets market are:

1. High Production Costs: The current cost of manufacturing IPS cell-derived platelets is very high, primarily due to the complex processes and expensive reagents involved. This economic challenge is a major barrier to widespread commercial adoption and affordability, especially in cost-sensitive healthcare systems.

2. Regulatory Hurdles and Long Approval Times: Navigating the complex regulatory landscape for novel cell-based therapies is a significant challenge. The need for extensive clinical trials and long-term safety data, coupled with evolving regulatory guidelines, can cause significant delays in product commercialization.

3. Technical Challenges in Product Standardization: Ensuring consistency and quality of IPS cell-derived platelets from different batches is a major technical challenge. Variations in cell lines, differentiation protocols, and final product characteristics can impact efficacy and safety, requiring rigorous quality control and standardization.

The IPS cell-derived platelets market is at a critical juncture, with strong drivers pushing for innovation and significant challenges to overcome. While the demand for a safe and scalable platelet source is clear, the high costs, regulatory complexities, and technical hurdles must be systematically addressed to realize the full potential of this groundbreaking technology and make it accessible to patients worldwide.

List of IPS Cell-derived Platelets Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies IPS cell-derived platelets companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the IPS cell-derived platelets companies profiled in this report include-

• Megakaryon Corporation
• Renerval Therapeutics
• Xueji Shengwu
• Help Therapeutics
• Cynata Therapeutics
• Fate Therapeutics
• Century Therapeutics

IPS Cell-derived Platelets Market by Segment

The study includes a forecast for the global IPS cell-derived platelets market by type, application, and region.

IPS Cell-derived Platelets Market by Type [Value from 2019 to 2031]:

• In Vivo Regeneration
• In Vitro Regeneration

IPS Cell-derived Platelets Market by Application [Value from 2019 to 2031]:

• Cancer
• Blood Disease
• Others

Country Wise Outlook for the IPS Cell-derived Platelets Market

The IPS cell-derived platelets market is experiencing significant progress, driven by the limitations of traditional donor-based platelet transfusions. This innovative field addresses challenges like short shelf life, risk of infectious diseases, and supply shortages by offering a scalable, safe, and readily available alternative for treating various bleeding disorders and for use in regenerative medicine.

• United States: The U.S. market is leading in advancements due to robust funding and a strong R&D infrastructure. Major developments include clinical trials and collaborations between biotech firms and academia, focusing on scaling up production and developing "off-the-shelf" allogeneic products for applications in fields like cardiology and neurology.
• China: China is a rapidly growing market for IPS cell-derived products, with increasing government support and investment in biotechnology. The focus is on building a robust R&D ecosystem and fostering partnerships to accelerate the development of cell therapies. While still in early stages, there is a strong push to catch up with global leaders.
• Germany: Germany's market is characterized by a strong regulatory framework and a focus on high-quality research. Recent developments include increased investment in regenerative medicine and partnerships between public institutions and private companies. The country is leveraging its expertise in biomanufacturing to optimize production processes for IPS cell-derived products.
• India: The Indian market is emerging, driven by a growing patient population with chronic diseases and rising awareness of advanced cell therapies. Recent developments include increased government funding for stem cell research and collaborations between local and international players. The country is focusing on establishing a foundation for R&D and clinical trials.
• Japan: Japan is a global leader in IPS cell research and commercialization, with government backing and key collaborations. Recent milestones include the first-in-human clinical trials for IPS cell-derived platelets. Companies are focusing on mass production techniques and developing universal-type platelets to overcome the challenges of HLA compatibility and supply.

Features of the Global IPS Cell-derived Platelets Market

• Market Size Estimates: Ips cell-derived platelets market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Ips cell-derived platelets market size by type, application, and region in terms of value ($B).
• Regional Analysis: Ips cell-derived platelets market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the IPS cell-derived platelets market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the IPS cell-derived platelets market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the IPS cell-derived platelets market by type (in vivo regeneration and in vitro regeneration), application (cancer, blood disease, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global IPS Cell-derived Platelets Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 In Vivo Regeneration: Trends and Forecast (2019-2031)
• 4.4 In Vitro Regeneration: Trends and Forecast (2019-2031)

5. Global IPS Cell-derived Platelets Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Cancer: Trends and Forecast (2019-2031)
• 5.4 Blood Disease: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global IPS Cell-derived Platelets Market by Region

7. North American IPS Cell-derived Platelets Market

• 7.1 Overview
• 7.2 North American IPS Cell-derived Platelets Market by Type
• 7.3 North American IPS Cell-derived Platelets Market by Application
• 7.4 United States IPS Cell-derived Platelets Market
• 7.5 Mexican IPS Cell-derived Platelets Market
• 7.6 Canadian IPS Cell-derived Platelets Market

8. European IPS Cell-derived Platelets Market

• 8.1 Overview
• 8.2 European IPS Cell-derived Platelets Market by Type
• 8.3 European IPS Cell-derived Platelets Market by Application
• 8.4 German IPS Cell-derived Platelets Market
• 8.5 French IPS Cell-derived Platelets Market
• 8.6 Spanish IPS Cell-derived Platelets Market
• 8.7 Italian IPS Cell-derived Platelets Market
• 8.8 United Kingdom IPS Cell-derived Platelets Market

9. APAC IPS Cell-derived Platelets Market

• 9.1 Overview
• 9.2 APAC IPS Cell-derived Platelets Market by Type
• 9.3 APAC IPS Cell-derived Platelets Market by Application
• 9.4 Japanese IPS Cell-derived Platelets Market
• 9.5 Indian IPS Cell-derived Platelets Market
• 9.6 Chinese IPS Cell-derived Platelets Market
• 9.7 South Korean IPS Cell-derived Platelets Market
• 9.8 Indonesian IPS Cell-derived Platelets Market

10. ROW IPS Cell-derived Platelets Market

• 10.1 Overview
• 10.2 ROW IPS Cell-derived Platelets Market by Type
• 10.3 ROW IPS Cell-derived Platelets Market by Application
• 10.4 Middle Eastern IPS Cell-derived Platelets Market
• 10.5 South American IPS Cell-derived Platelets Market
• 10.6 African IPS Cell-derived Platelets Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global IPS Cell-derived Platelets Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Megakaryon Corporation
  • Company Overview
  • IPS Cell-derived Platelets Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Renerval Therapeutics
  • Company Overview
  • IPS Cell-derived Platelets Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Xueji Shengwu
  • Company Overview
  • IPS Cell-derived Platelets Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Help Therapeutics
  • Company Overview
  • IPS Cell-derived Platelets Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Cynata Therapeutics
  • Company Overview
  • IPS Cell-derived Platelets Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Fate Therapeutics
  • Company Overview
  • IPS Cell-derived Platelets Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Century Therapeutics
  • Company Overview
  • IPS Cell-derived Platelets Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us